EconBiz - Find Economic Literature
    • Logout
    • Change account settings
  • A-Z
  • Beta
  • About EconBiz
  • News
  • Thesaurus (STW)
  • Academic Skills
  • Help
  •  My account 
    • Logout
    • Change account settings
  • Login
EconBiz - Find Economic Literature
Publications Events
Search options
Advanced Search history
My EconBiz
Favorites Loans Reservations Fines
    You are here:
  • Home
  • Search: subject:"Antiretrovirals"
Narrow search

Narrow search

Year of publication
Subject
All
Antiretrovirals 26 HIV-infections 13 therapeutic use 12 treatment 12 antiretrovirals 9 Cost-analysis 6 Darunavir 6 Peptide-hydrolase-inhibitors 6 Pharmacoeconomics 6 Ritonavir 6 AIDS 5 Acquired-immunodeficiency-syndrome 5 Cost-utility 5 HIV 5 Cost-effectiveness 3 HIV infections 3 Lopinavir 3 Non-nucleoside-reverse-transcriptase-inhibitors 3 Spain 3 Aids 2 Botswana 2 Budget-impact-analysis 2 Cost analysis 2 Cost effectiveness 2 Cost-of-illness 2 Ganciclovir 2 HIV-1-infections 2 HIV/AIDS 2 Lamivudine 2 Medicaid 2 Modelling 2 Nucleoside-reverse-transcriptase-inhibitors 2 cost-analysis 2 fixed-dose combination 2 global health 2 innovation 2 pharmceutical philanthropy 2 ARVs 1 Acquired immunodeficiency syndrome 1 Adefovir 1
more ... less ...
Online availability
All
Undetermined 32 Free 3
Type of publication
All
Article 35 Book / Working Paper 2
Type of publication (narrower categories)
All
Article in journal 3 Aufsatz in Zeitschrift 3 Arbeitspapier 1 Article 1 Graue Literatur 1 Non-commercial literature 1 Working Paper 1 research-article 1
more ... less ...
Language
All
Undetermined 31 English 5 French 1
Author
All
Smets, Erik 6 Allegri, Gabriele 3 Hill, Andrew M. 3 Lothgren, Mickael Lthgren 3 Lozano, Virginia 3 Oyagüez, Itziar 3 Pareja, Antonio 3 Annemans, Lieven 2 Chabrol, Fanny 2 Colin, Xavier 2 Costagliola, Dominique 2 Guillon, Pascal 2 Hemmett, Lindsay 2 Homar, Franc 2 Lafuma, Antoine 2 Marínez-Gómez, Juan 2 Mauskopf, Josephine 2 Moeremans, Karen 2 Anceau, Anne 1 Ausayakhun, Somsanguan 1 Battegay, Manuel 1 Bayoumi, Ahmed M. 1 Beck, Eduard J. 1 Bentley, Anthony 1 Boyd, Mark A. 1 Brent, Robert J. 1 Brogan, Anita 1 Busby, Josh 1 Caekelbergh, Karin 1 Calleri, Guido 1 Campostrini, Stefano 1 Carratalá, Carmen 1 Casado, Miguel 1 Coulibaly, Ibrahima 1 Dakin, Helen 1 Das, Keshab 1 Duggan, Mark 1 Duggan, Mark G 1 Encinosa, William 1 Evans, William 1
more ... less ...
Published in...
All
PharmacoEconomics 19 Disease Management and Health Outcomes 3 Applied Health Economics and Health Policy 2 Forum for Health Economics & Policy 2 Health Economics Review 2 Applied economics 1 Health economics review 1 Mondes en développement 1 Revue Tiers-Monde 1 Revue tiers monde 1 Social Science & Medicine 1 The Patient: Patient-Centered Outcomes Research 1 Working Papers 1 Working paper / Gujarat Institute of Development Research 1
more ... less ...
Source
All
RePEc 31 ECONIS (ZBW) 4 EconStor 1 Other ZBW resources 1
Showing 1 - 10 of 37
Cover Image
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
Homar, Franc; Lozano, Virginia; Marínez-Gómez, Juan; … - In: Health Economics Review 2 (2012) 16, pp. 1-9
Background: The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative is to administer the individual components of the FDCs separately, thus...
Persistent link: https://www.econbiz.de/10010317150
Saved in:
Cover Image
Using the travel cost method to value visits and stigma in connection with ARV adherence in Uganda
Brent, Robert J. - In: Applied economics 49 (2017) 5, pp. 477-497
Persistent link: https://www.econbiz.de/10011810687
Saved in:
Cover Image
Making Markets for Merit Goods: The Political Economy of Antiretrovirals
Kapstein, Ethan B.; Busby, Josh - 2009
This paper examines the role of policy entrepreneurs and global activists in shaping the international market for antiretroviral drugs to combat HIV/AIDS. When ARVs first came on the market in the 1990s they were exceedingly expensive; the cost of treatment was upwards of $10,000 per year. These...
Persistent link: https://www.econbiz.de/10008528572
Saved in:
Cover Image
Les antirétroviraux au Botswana. Observatoire des mutations de l'intervention internationale sur la santé en Afrique
Chabrol, Fanny - In: Revue Tiers-Monde n°215 (2013) 3, pp. 17-34
</titre> By focusing on access to free antiretroviral treatments in Botswana, this article analyses recent transformations of international cooperation on health issues. The partnership between the government of Botswana, the pharmaceutical company Merck & Co and the Bill and Melinda Gates Foundation...
Persistent link: https://www.econbiz.de/10011187766
Saved in:
Cover Image
Les antirétroviraux au Botswana : observatoire des mutations de l'intervention internationale sur la santé en Afrique
Chabrol, Fanny - In: Revue tiers monde 215 (2013), pp. 17-34
Persistent link: https://www.econbiz.de/10010201286
Saved in:
Cover Image
L'accès aux traitements antisida en Afrique : une analyse de la stratégie de brevet des entreprises multinationales
Guennif, Samira; Mfuka, Claude - In: Mondes en développement 131 (2005) 3, pp. 75-86
According to Attaran and Gillespie-White (2001), there is no link between patents and poor access to HIV/AIDS treatments in Africa since multinationals patent a few. Questioning what the authors call the rule and the exceptions, this paper shows that multinationals use patents as entry barriers...
Persistent link: https://www.econbiz.de/10005237303
Saved in:
Cover Image
Mind the gap: Access to ARV medication, rights and the politics of scale in South Africa
Jones, Peris Sean - In: Social Science & Medicine 74 (2012) 1, pp. 28-35
Global access to anti-retroviral medication (ARVs) has increased exponentially in recent years. As a relatively recent phenomenon for the global South, much knowledge is being added, but analysis of ‘access’ to ARVs remains partial. The main research objective of this article is to gain a...
Persistent link: https://www.econbiz.de/10011042643
Saved in:
Cover Image
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
Homar, Francesc; Lozano, Virginia; Martínez-Gómez, Juan; … - In: Health Economics Review 2 (2012) 1, pp. 1-9
Our study suggests that the discontinuation of FDC treatment and the replacement with the administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs. </AbstractSection> Copyright Homar...
Persistent link: https://www.econbiz.de/10010998789
Saved in:
Cover Image
Budget Impact Analysis of Switching to Darunavir/Ritonavir Monotherapy for HIV-Infected People in Spain
Pasquau, Juan; Gostkorzewicz, Joana; Ledesma, Francisco; … - In: Applied Health Economics and Health Policy 10 (2012) 2, pp. 139-141
Persistent link: https://www.econbiz.de/10009647779
Saved in:
Cover Image
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
Homar, Franc; Lozano, Virginia; Marínez-Gómez, Juan; … - In: Health economics review 2 (2012) 16, pp. 1-9
Background: The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative is to administer the individual components of the FDCs separately, thus...
Persistent link: https://www.econbiz.de/10009752877
Saved in:
  • 1
  • 2
  • 3
  • 4
  • Next
  • Last
A service of the
zbw
  • Sitemap
  • Plain language
  • Accessibility
  • Contact us
  • Imprint
  • Privacy

Loading...